Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MACROGENICS INCMGNX · Entity 6104 | Sr VP, Technical Ops | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MACROGENICS INC
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,543 |
Ending reported balance
After 2026-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-15 · Exercise / conversion · Acquired 13,332 · Balance 44,063 F1: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. Row 2 · 2026-02-15 · Tax withholding · Disposed 5,520 · Balance 38,543 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-15 · Exercise / conversion · Disposed 13,332 · Balance 0 F1: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 25,000 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Grant · Acquired 25,000 · Balance 25,000 F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-02-12 | Direct | 150,000 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Grant · Acquired 150,000 · Balance 150,000 F3: 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.
F3: 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2017 Filed Feb 16, 2017 22:45 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantCommon Stock · Derivative | 45,000 | $20.53 Strike: $20.53 | $923,850.00 |
DisclosureSEC source: 0001125345-17-000033 · wf-form4_148728512685526.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 22:12 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001552781-16-001952 · e00508_spitznagel-form4.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: 12.5% of the option becomes exercisable on March 14, 2017 and the remaining 87.5% vests in 14 substantially equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.